CD34 |
Acute myeloid leukemia (AML) |
Immunoaffinity capture |
Higher levels of CD34+ exosomes in AML patients |
Plasma |
[117] |
EDIL-3/Del1 |
Bladder cancer |
Western blot |
Elevated expression in patients with high-grade bladder cancer |
Urine |
[118] |
miR-101, 372, 373 |
Breast cancer |
qRT-PCR |
Highly expressed in breast cancer patients and elevated miR-373 expression in receptor-negative breast cancer patients |
Serum |
[119] |
miR-21, 146a |
Cervical cancer |
qRT-PCR |
Elevated expression in exosomes from cervical cancer patients than healthy controls and HPV(+) subjects |
Cervicovaginal lavages |
[120] |
Let-7a, miR-1229, 1246, 150, 21, 223, 23a |
Colon cancer |
qRT-PCR |
Highly expressed in exosomes from colon cancer patients |
Serum |
[121] |
CD147, CD9 |
Colon cancer |
Exoscreen |
Higher levels of CD147/CD9 double-positive extracellular vesicles in cancer patients than healthy controls |
Serum |
[122] |
miR-17-92a cluster |
Colon cancer |
qRT-PCR |
Elevated expression in cancer patients and higher levels predict poorer prognoses |
Serum |
[123] |
miR-21 |
Esophageal squamous cell carcinoma (ESCC) |
qRT-PCR |
Exosomal levels of miR-21 are significantly higher in patients with ESCC than those with benign diseases |
Serum |
[80] |
LINC00152 |
Gastric cancer |
qRT-PCR |
Elevated expression levels in gastric cancer patients than healthy controls |
Plasma |
[83] |
EGFRvIII (mRNA) |
Glioblastoma |
Nested RT-PCR |
Mutated EGFRvIII could be detected in exosomes from 7 of 25 glioblastoma patients but not that from 30 healthy subjects |
Serum |
[75] |
miR-718 |
Hepatocellular carcinoma (HCC) |
qRT-PCR |
Decreased expression of miR-718 in exosomes from HCC cases with recurrence after liver transplantation compared with those without recurrence |
Serum |
[124] |
miR-21 |
Hepatocellular carcinoma (HCC) |
qRT-PCR |
Higher exosomal levels in patients with HCC than those with hepatitis or healthy controls |
Serum |
[125] |
miR-17-3p, 21, 106a, 146, 155, 191, 192, 203, 205, 210, 212, 214 |
Lung cancer |
miRNA array |
Total exosome and miRNA levels are upregulated in lung cancer patients and these 12 miRNAs could be detected in exosomes |
Plasma |
[76] |
LRG1 |
Lung cancer |
Western blot |
Patients with non-small cell lung cancer have an increased LRG1 expression in exosomes compared to healthy controls |
Urine |
[126] |
TYRP2, VLA-4, Hsp70, MET |
Melanoma |
Western blot, multiplex protein analysis |
The levels of these 4 proteins are increased in exosomes from stage III and IV patients compared to stage I patients as well as healthy controls |
Plasma |
[39] |
CD63, caveolin-1 |
Melanoma |
In-house sandwich ELISA (Exotest) |
Melanoma patients have more CD63- and caveolin-1-positive exosomes compared to healthy controls |
Plasma |
[127] |
Galectin-9 |
Nasopharyngeal carcinoma (NPC) |
Western blot |
Exosomes from NPC patients but not that from healthy controls contain galectin-9 |
Serum |
[128] |
Claudin-4 |
Ovarian cancer |
Western blot |
Claudin-4 could be detected in exosomes from 32 of 63 ovarian cancer patients but only 1 of 50 healthy controls |
Plasma |
[129] |
miR-21, 141, 200a, 200b, 200c, 203, 205, 214 |
Ovarian cancer |
miRNA array |
The levels of these 8 miRNAs are elevated in exosomes from ovarian cancer patients compared to healthy controls and benign tumors |
Serum |
[72] |
miR-1246, 4644, 3976, 4306 |
Pancreatic cancer |
qRT-PCR |
Upregulated expression in pancreatic cancer patients compared to healthy controls |
Serum |
[130] |
PTEN |
Prostate cancer |
Western blot |
PTEN is exclusively expressed in exosomes of prostate cancer patients compared to healthy controls |
Plasma |
[131] |
Survivin |
Prostate cancer |
Western blot, ELISA |
Prostate cancer patients have more survivin-positive exosomes compared to healthy controls as well as patients with benign prostatic hyperplasia |
Plasma |
[132] |
PSA, PSMA |
Prostate cancer |
Western blot |
Detected in 20 of 24 exosomes from prostate cancer patients but not in healthy controls |
Urine |
[133] |
miR-1290, miR-375 |
Prostate cancer |
qRT-PCR |
Highly expressed in castration-resistant prostate cancer patients and their levels are significantly associated with poor overall survival |
Plasma |
[134] |
LncRNA-p21 |
Prostate cancer |
qRT-PCR |
Higher level of exosomal lncRNA-p21 in patients with prostate cancer than those with benign hyperplasia |
Plasma |
[135] |